- Home
- PMF vs ABEO Comparison
PMF vs ABEO Comparison
Compare PMF & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMF
- ABEO
- Stock Information
- Founded
- PMF 2001
- ABEO N/A
- Country
- PMF United States
- ABEO United States
- Employees
- PMF N/A
- ABEO N/A
- Industry
- PMF Finance/Investors Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PMF Finance
- ABEO Health Care
- Exchange
- PMF Nasdaq
- ABEO Nasdaq
- Market Cap
- PMF 234.4M
- ABEO 247.8M
- IPO Year
- PMF N/A
- ABEO 1980
- Fundamental
- Price
- PMF $8.92
- ABEO $5.61
- Analyst Decision
- PMF
- ABEO Strong Buy
- Analyst Count
- PMF 0
- ABEO 3
- Target Price
- PMF N/A
- ABEO $18.00
- AVG Volume (30 Days)
- PMF 61.3K
- ABEO 177.7K
- Earning Date
- PMF 01-01-0001
- ABEO 11-14-2024
- Dividend Yield
- PMF 5.36%
- ABEO N/A
- EPS Growth
- PMF N/A
- ABEO N/A
- EPS
- PMF N/A
- ABEO N/A
- Revenue
- PMF N/A
- ABEO N/A
- Revenue This Year
- PMF N/A
- ABEO N/A
- Revenue Next Year
- PMF N/A
- ABEO $18,714.71
- P/E Ratio
- PMF N/A
- ABEO N/A
- Revenue Growth
- PMF N/A
- ABEO 147.52
- 52 Week Low
- PMF $7.69
- ABEO $3.05
- 52 Week High
- PMF $10.56
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- PMF 26.33
- ABEO 34.07
- Support Level
- PMF $8.85
- ABEO $5.45
- Resistance Level
- PMF $9.96
- ABEO $5.79
- Average True Range (ATR)
- PMF 0.20
- ABEO 0.18
- MACD
- PMF -0.03
- ABEO -0.02
- Stochastic Oscillator
- PMF 7.12
- ABEO 20.34
About PMF PIMCO Municipal Income Fund
PIMCO Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to seek to provide current income exempt from federal income tax. The fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal income tax.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.